Resources 
    • About Us 

    • Home Report Store Pharmaceutical Contract Development and Manufacturing Market
    Pharmaceutical Contract Development and Manufacturing Market

    Pharmaceutical Contract Development & Manufacturing Market Size, Share, Forecast, & Trends Analysis by Service (Manufacturing [API, FDF {Parenteral, Injectable, Tablet, Capsule, Oral Liquid, Biologics}], Drug Development) End User - Global Forecast to 2031

    Report ID:MRHC - 104477 Pages: 250 Aug-2024 Formats*: PDF Category: Healthcare Delivery: 24 to 48 Hours

    The Pharmaceutical Contract Development and Manufacturing Market was valued at $146.14 billion in 2023. This market is expected to reach $261.57 billion by 2031 from an estimated $158.27 billion in 2024, at a CAGR of 7.4% during the forecast period of 2024-2031.

    Pharmaceutical Contract Development and Manufacturing Market Size & Forecast

    The growth of this market can be attributed to various factors, such as complex manufacturing requirements of the pharmaceutical industry, manufacturers growing inclination towards the use of cutting-edge technologies, increasing investments in pharmaceutical R&D, patent expiration, and rising demand for generic medicines and biologics. Furthermore, growing demand for cell therapies, gene therapies, and personalized medicines and growth in high potency active pharmaceutical ingredients (HPAPI) and antibody-drug conjugates (ADC) markets are expected to offer growth opportunities.

    Pharmaceutical Contract Development and Manufacturing Market Growth Drivers

    Increasing Investments in Pharmaceutical R&D

    Pharmaceutical companies are allocating significant resources for R&D purposes. This funding is mainly driven by the rising prevalence of chronic diseases due to the growing geriatric population, complexities in clinical trials, and higher failure of drugs in early-phase studies. The increasing funding for R&D purposes is leading to accelerated drug discovery and manufacturing, thereby driving the need for contract manufacturing and development organizations. According to the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), pharmaceutical R&D expenditure is expected to reach USD 213 billion by 2026 from USD 189 billion in 2022. Additionally, governments around the world are ramping up their investments in pharmaceutical and biopharmaceutical research. Various national governments have also launched initiatives to enhance pharmaceutical R&D.

    For instance, in March 2023, the Canadian government allocated USD 59 million to the Canadian Critical Drug Initiative to advance drug research and commercialization. Such initiatives are anticipated to drive higher demand for pharmaceutical CDMOs to support efficient manufacturing processes.

    Pharmaceutical Contract Development & Manufacturing Market

    Click here to: Get Free Sample Pages of this Report

    Complex Manufacturing Requirements of the Pharmaceutical Industry

    The pharmaceutical industry is driven mainly by scientific advancements and discoveries in conjunction with clinical and toxicological expertise. In addition to the complex nature of the pharmaceutical manufacturing process, multiple countries offer distinct legal safeguards for exclusive medications and production techniques, commonly referred to as intellectual property rights. Extensive government rules are in place in many countries that impact the development and approval of medications intended for commercial sale. To protect the integrity of drug manufacturing processes and the efficacy, safety, and quality of pharmaceutical goods, these countries have stringent regulations for good manufacturing practices. Due to these difficulties, pharmaceutical companies are now developing and producing medicines and biologics in collaboration with contract manufacturing and development firms.

    Pharmaceutical Contract Development and Manufacturing Market Trends

    Integration of Process Automation

    Process automation involves utilizing software and technologies to streamline business processes and functions, ensuring a consistent workflow and achieving specific tasks. In Contract Development and Manufacturing Organizations (CDMOs), process automation is essential for managing, controlling, and optimizing manufacturing activities. This automation leverages sensors, software, and programmable logic controllers (PLCs) to enhance operations. By integrating these technologies, organizations can centralize and analyze data from sensors, monitor production lines in real time, and improve quality. During the manufacturing process, automated systems look for inconsistencies. If any are found, production is halted to protect workers and preserve product quality.

    Additionally, process automation helps eliminate bottlenecks, boost efficiency, and reduce time and costs. These benefits are driving the industry's growing adoption of process automation technology.

    Capacity Expansion and Deals to Acquire New Facilities

    Capacity expansion is a strategic move of an organization that involves decisions like increasing production capabilities, investment in new units, and adoption or implementation of new technology and equipment. The increase in the number of acquisitions, collaborations, and mergers among CDMOs is a response to some of the major challenges the pharmaceutical industry faces in the development process of drugs, such as the growing number of expiring patents, increasing R&D costs, and increasing prevalence of chronic diseases. Some of the recent strategic developments are as follows:

    • In January 2024, WuXi STA (China) opened two new peptide manufacturing plants in China: one in Changzhou and another at their new site in Taixing. This expansion has increased the company’s manufacturing capacity.
    • In December 2023, AGC Inc. (Japan) expanded a biopharmaceutical CDMO capability at AGC Yokohama Technical Center in Yokohama, Japan.

    Pharmaceutical Contract Development and Manufacturing Market Opportunities

    Growing Demand for Cell and Gene Therapies and Personalized Medicines

     Next-generation medicines, such as cell and gene therapy, provide significant opportunities for growth in the CDMO market. Cell therapies can benefit patients with neurological disorders, cancer, autoimmune diseases, infectious diseases, urinary tract issues, and compromised immune systems. The need for CDMOs is rising as the number of gene therapy approvals is steadily rising.

    The U.S. FDA reports that as of March 2024, 36 gene treatments had received FDA approval, compared to 34 in 2023. A significant barrier to the growth of the cell and gene therapy market is a lack of manufacturing capacity, so large companies outsource the development of their cell or gene therapy processes, creating profitable opportunities for the expansion of the pharmaceutical contract development and manufacturing market.

    Pharmaceutical Contract Development and Manufacturing Market Analysis: Key Findings

    By Type: In 2024, the Pharmaceutical Manufacturing Services Segment to Dominate the Pharmaceutical Contract Development and Manufacturing Market

    Based on type, the pharmaceutical contract development and manufacturing market is segmented into pharmaceutical manufacturing services, drug development services, and biologics manufacturing services. In 2024, the pharmaceutical manufacturing services segment is expected to account for the largest share of 75.6% of the pharmaceutical contract development and manufacturing market. The complex requirements of the manufacturing process, in addition to the high cost associated with drug manufacturing, are increasing the outsourcing of manufacturing services. Small and medium-sized pharmaceutical companies need more manufacturing infrastructure and require technical expertise. Small and medium-sized pharmaceutical companies can lower production costs and uphold medical quality standards by outsourcing to CDMOs. Pharmaceutical firms can focus on their core capabilities by using CDMOs to streamline their manufacturing process, from manufacture to secondary packaging.

    However, the biologics manufacturing services segment is estimated to register the highest CAGR of 11.1% during the forecast period. Biologics are becoming progressively more in demand due to their advantages, which include high activity and specificity, few side effects, and the capacity to target particular molecules. The need for manufacturing biologics is growing as these are used in treating infectious, autoimmune, and cardiovascular diseases, and different types of cancers.

    The U.S. Food and Drug Administration (FDA) reports that over the last five years, the approval of biologics has increased and now makes up over 25% of all drug approvals; in 2022, 15 biologics were approved out of a total of medicines, up from 13 in 2020. Moreover, the intricacy involved in producing biologics is leading to a rise in outsourcing to CDMOs. CDMO successfully handles issues including scaling up, potential for contamination, and stringent analytical testing. Therefore, it is anticipated that the growth of biologics manufacturing services will be aided by an increase in the percentage of approved biologics, an increase in the complexity of production, and government funding in biologics R&D.

    By End User: In 2024, the Large Pharmaceutical Companies Segment to Dominate the Pharmaceutical Contract Development and Manufacturing Market

    Based on end user, the pharmaceutical contract development and manufacturing market is segmented into large pharmaceutical companies, small & mid-size pharmaceutical companies, and generic pharmaceutical companies. In 2024, the large pharmaceutical companies segment is expected to account for the largest share of 42.3% of the pharmaceutical contract development and manufacturing market. The primary drivers accounting for the largest market share of this segment are the increasing demand for modern technology and the emphasis on expanding worldwide in business. Since CDMOs have facilities spread across multiple regions, they are a major source of manufacturing support for large pharmaceutical businesses looking to expand geographically. Due to the increasing complexity of drug research and the rising expenses of building and maintaining those facilities, large biotech and pharmaceutical companies are finding it increasingly necessary to rely on outside contract manufacturers for help running their intricate operations.

    Geographical Analysis

    In 2024, North America to Dominate the Market

    In 2024, North America is expected to account for the largest share of 44.3% of the pharmaceutical contract development and manufacturing market. This region’s large market share is attributed to factors such as the presence of large pharmaceutical and biotechnology manufacturers, biopharmaceutical R&D funding, and rising demand for cell and gene therapies. The region's biopharmaceutical production facilities have grown as a result of the growing demand for biopharmaceuticals and supportive activities for their adoption. Drug shortages are an important concern for consumers in the United States. Drug shortages can be caused by a variety of factors, including delays, discontinuations, and issues with manufacturing and quality.

    The U.S. FDA reports that in 2023 there were 98 medicine shortages as opposed to 79 in 2021. Many pharmaceutical companies in the United States are depending on CDMOs to prevent medicine shortages.

    Moreover, Asia-Pacific is poised to register the highest CAGR of 8.8% during the forecast period. The region's rapid growth can be attributed to increased awareness of overall health and treatment availability, improved healthcare infrastructure, a growing geriatric population, low-cost manufacturing advantages, rising pharmaceutical R&D expenditure, increased government funding for drug development and research, and rising healthcare spending in the region. The governments of this region are focusing on improving healthcare infrastructure in order to improve patient safety.

    In 2022–2023, the Government of India approved 13 foreign direct investment (FDI) proposals, which led to USD 281,400 in foreign investment in the pharmaceutical sector for brownfield projects. These government initiatives and other factors are expected to drive growth in pharmaceutical CDMOs in the Asia-Pacific region.

    Pharmaceutical Contract Development and Manufacturing Market: Key Companies

    The report offers a competitive landscape based on an extensive assessment of the product offerings and geographic presence of leading market players and the key growth strategies adopted by them over the past few years. The key players operating in the pharmaceutical contract development and manufacturing market are Lonza Group Ltd. (Switzerland), Catalent Inc. (U.S.), Patheon (Subsidiary of Thermo Fisher Scientific Inc. (U.S.), Recipharm AB (Sweden), C.H. Boehringer Sohn AG & CO. KG. (Germany), Aurobindo Pharma ltd (India), Jubilant Pharmova Limited (India), Fareva SA (Luxembourg), Vetter Pharma International GmbH (Germany), Aenova Group (Germany), WuXi Biologics Inc. (China), Piramal Enterprises Limited (India), Almac Group (U.K.), Fabbrica Italiana Sintetici S.p.A. (F.I.S.) (Italy), Samsung Biologics Co., Ltd (South Korea), Cambrex Corporation (U.S.), Siegfried Holdings AG (Switzerland), FUJIFILM Diosynth Biotechnologies (Japan), and Curia Global, Inc. (U.S.).

    Pharmaceutical Contract Development and Manufacturing Market Overview: Latest Developments from Key Industry Players

    • In July 2024, Siegfried Holdings AG Holding (Switzerland) acquired Curia Global Inc.'s CDMO location in Wisconsin (U.S.) to enhance drug substance capabilities.
    • In June 2024, Vetter Pharma (Germany) expanded manufacturing sites in the US and Germany. These facilities are expected to be completely operational in 2030. The development is expected to boost the company's footprint in the US market.
    • In March 2024, Lonza Group (Switzerland) agreed to pay USD 1.2 billion to Genentech, Inc. (US), a subsidiary of F. Hoffmann-La Roche AG, for the biologics production plant in California. The acquisition is planned to boost the company's large-scale biologics manufacturing capabilities for mammalian medicines and broaden its regional presence in the U.S.
    • In September 2023, Samsung Biologics (South Korea) signed an agreement with Bristol Myers Squibb (U.S.) for commercial production of antibody cancer drug substances.

    Pharmaceutical Contract Development and Manufacturing Market Research Summary

    Particulars

    Details

    Number of Pages

     ~250

    Format

     PDF

    Forecast Period

     2024-2031

    Base Year

     2023

    CAGR

     7.4%

    Estimated Market Size (Value)

     $261.57 billion by 2031

    Segments Covered

     By Type

    • Pharmaceutical Manufacturing Services
      • Active Pharmaceutical Ingredient (API) Manufacturing Services
      • Finished Dosage Forms (FDF) Manufacturing Services
        • Parenteral/Injectable Manufacturing Services
        • Tablet Manufacturing Services
        • Capsule Manufacturing Services
        • Oral Liquid Manufacturing Services
        • Other Formulations
    • Drug Development Services
    • Biologics Manufacturing Services
      • Active Pharmaceutical Manufacturing Services (API) Manufacturing Services
      • Finished Dosage Form Manufacturing (FDF) Services     
        (Note: Other formulations include topical formulations, powder formulations, and modified-release dosage forms.)

     By End User

    • Large Pharmaceutical Companies
    • Small & Mid-size Pharmaceutical Companies
    • Generic Pharmaceutical Companies

    Countries Covered

    North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, Switzerland, Netherlands, Denmark, and Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, Singapore, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Rest of Latin America), and Middle East & Africa.

    Key Companies

    are Lonza Group Ltd. (Switzerland), Catalent Inc. (U.S.), Patheon (Subsidiary of Thermo Fisher Scientific Inc. (U.S.), Recipharm AB (Sweden), C.H. Boehringer Sohn AG & CO. KG. (Germany), Aurobindo Pharma ltd (India), Jubilant Pharmova Limited (India), Fareva SA (Luxembourg), Vetter Pharma International GmbH (Germany), Aenova Group (Germany), WuXi Biologics Inc. (China), Piramal Enterprises Limited (India), Almac Group (U.K.), Fabbrica Italiana Sintetici S.p.A. (F.I.S.) (Italy), Samsung Biologics Co., Ltd (South Korea), Cambrex Corporation (U.S.), Siegfried Holdings AG (Switzerland), FULJIFILM Diosynth Biotechnologies (Japan), and Curia Global, Inc. (U.S.), WuXi Biologics Inc. (China), Piramal Enterprises Limited (India), Almac Group (U.K.), Fabbrica Italiana Sintetici S.p.A. (F.I.S.) (Italy), Samsung Biologics Co., Ltd (South Korea), Cambrex Corporation (U.S.), Siegfried Holdings AG (Switzerland), FULJIFILM Diosynth Biotechnologies (Japan), and Curia Global, Inc. (U.S.).

    Key questions answered in the pharmaceutical contract development and manufacturing market report:

    The pharmaceutical contract development and manufacturing market report covers the qualitative and quantitative analysis of the market. This report involves analyzing various segments of pharmaceutical contract development and manufacturing, such as type, end user, and regional and country-level studies. The report also provides insights on factors impacting market growth, regulatory analysis, factor analysis, and Porter’s five forces analysis.

    The pharmaceutical contract development and manufacturing market is projected to reach $261.57 billion by 2031 at a CAGR of 7.4% from 2024 to 2031.

    Among all the types studied in this report, in 2024, the pharmaceutical manufacturing services segment is expected to account for the largest share, 75.6%, of the pharmaceutical contract development and manufacturing market. The largest share of the segment is attributed to increasing investment in R&D, the need to reduce manufacturing costs, and the increase in demand for high-volume drug manufacturing.

    The growth of this market can be attributed to various factors, such as complex manufacturing requirements of the pharmaceutical industry, manufacturers' growing inclination towards the use of innovative technologies, increasing investments in pharmaceutical R&D, patent expiration, and rising demand for generic medicines and biologics are expected to drive the growth of the market. Furthermore, growing demand for cell therapies, gene therapies, and personalized medicines growth in high potency active pharmaceutical ingredients (HPAPI) and antibody-drug conjugates (ADC) markets are expected to offer growth opportunities.

    The key players operating in the pharmaceutical contract development and manufacturing market are Lonza Group Ltd. (Switzerland), Catalent Inc. (U.S.), Patheon (Subsidiary of Thermo Fisher Scientific Inc. (U.S.), Recipharm AB (Sweden), C.H. Boehringer Sohn AG & CO. KG. (Germany), Aurobindo Pharma ltd (India), Jubilant Pharmova Limited (India), Fareva SA (Luxembourg), Vetter Pharma International GmbH (Germany), Aenova Group (Germany), WuXi Biologics Inc. (China), Piramal Enterprises Limited (India), Almac Group (U.K.), Fabbrica Italiana Sintetici S.p.A. (F.I.S.) (Italy), Samsung Biologics Co., Ltd (South Korea), Cambrex Corporation (U.S.), Siegfried Holdings AG (Switzerland), FUJIFILM Diosynth Biotechnologies (Japan), and Curia Global, Inc. (U.S.).

    Among all the geographies studied in this report, Asia-Pacific is expected to register the highest CAGR of 8.8% during the forecast period. This region’s growth is attributed to its growing geriatric population, rising awareness of overall health and treatment availability, growing healthcare spending, improving healthcare infrastructure, low-cost manufacturing advantages, rising pharmaceutical R&D expenditure, and increasing government funding for drug development and research.

    Enquire
    Check Discount
    Related Tag: Pharmaceutical Contract Development and Manufacturing Market CDMO CRAMS Pharmaceutical CDMO Pharmaceutical CMO Pharmaceutical Contract Manufacturing Pharmaceutical Outsourcing Pharmaceutical Contract Manufacturing Services
    Processing & Packaging Technologies
    Healthcare

    1.   Introduction
        1.1.   Market Definition & Scope
        1.2.   Market Ecosystem
        1.3.   Currency and Limitations
        1.4.   Key Stakeholders

    2.   Research Methodology
        2.1.   Research Approach
        2.2.   Process of Data Collection & Validation
            2.2.1.   Secondary Research
            2.2.2.   Primary Research/Interviews with Key Opinion Leaders from the Industry
        2.3.   Market Sizing and Forecasting
            2.3.1.   Market Size Estimation Approach
            2.3.2.   Growth Forecast Approach
            2.3.3.   Market Share Analysis
        2.4.   Assumptions for the Study

    3.   Executive Summary

    4.   Market Insights
        4.1.   Overview
        4.2.   Drivers
            4.2.1.   Complex Manufacturing Requirements of the Pharmaceutical Industry
            4.2.2.   Manufacturers' Growing Inclination Towards the Use of Cutting-Edge Technologies
            4.2.3.   Increasing Investments in Pharmaceutical R&D
            4.2.4.   Patent Expiration
            4.2.5.   Rising Demand for Generic Medicines and Biologics
        4.3.   Restraints
            4.3.1.   Disruption in Supply Chain
            4.3.2.   Stringent Government Regulations
        4.4.   Opportunities
            4.4.1.   Growing Demand for Cell Therapies, Gene Therapies, and Personalized Medicines
            4.4.2.   Growth in High Potency Active Pharmaceutical Ingredients (HPAPI) and Antibody-drug Conjugates (ADC) Markets
        4.5.   Challenges
            4.5.1.   Intellectual Property Risks
            4.5.2.   Shortage of Skilled Professionals
        4.6.   Factor Analysis
        4.7.   Trends
            4.7.1.   Integration of Process Automation
            4.7.2.   Digital Automation
            4.7.3.   Capacity Expansion and Deals to Acquire New Facilities
        4.8.   Regulatory Analysis
        4.9.   Value Chain Analysis
        4.10.   Porter’s Five Force Analysis

    5.   Pharmaceutical Contract Development and Manufacturing Market Assessment—by Type
        5.1.   Overview
        5.2.   Pharmaceutical Manufacturing Services
            5.2.1.   Active Pharmaceutical Ingredient (API) Manufacturing Services
            5.2.2.   Finished Dosage Forms (FDF) Manufacturing Services
                5.2.2.1.   Parenteral/Injectable Manufacturing Services
                5.2.2.2.   Tablet Manufacturing Services
                5.2.2.3.   Capsule Manufacturing Services
                5.2.2.4.   Oral Liquid Manufacturing Services
                5.2.2.5.   Other Formulations
        5.3.   Drug Development Services
        5.4.   Biologics Manufacturing Services
            5.4.1.   Active Pharmaceutical Manufacturing Services (API) Manufacturing Services
            5.4.2.   Finished Dosage Form Manufacturing (FDF) Services

    6.   Pharmaceutical Contract Development and Manufacturing Market Assessment—by End Users
        6.1.   Overview
        6.2.   Large Pharmaceutical Companies
        6.3.   Small & Mid-Size Pharmaceutical Companies
        6.4.   Generic Pharmaceutical Companies

    7.   Pharmaceutical Contract Development and Manufacturing Market Assessment—by Geography
        7.1.   Overview
        7.2.   North America
            7.2.1.   U.S.
            7.2.2.   Canada
        7.3.   Europe
            7.3.1.   Germany
            7.3.2.   France
            7.3.3.   U.K.
            7.3.4.   Italy
            7.3.5.   Spain
            7.3.6.   Switzerland
            7.3.7.   Netherlands
            7.3.8.   Denmark
            7.3.9.   Rest of Europe (RoE)
        7.4.   Asia-Pacific
            7.4.1.   Japan
            7.4.2.   China
            7.4.3.   India
            7.4.4.   South Korea
            7.4.5.   Australia
            7.4.6.   Singapore
            7.4.7.   Rest of Asia-Pacific (RoAPAC)
        7.5.   Latin America
            7.5.1.   Brazil
            7.5.2.   Mexico
            7.5.3.   Rest of Latin America (RoLATAM)
        7.6.   Middle East & Africa

    8.   Competition Analysis
        8.1.   Overview
        8.2.   Key Growth Strategies
        8.3.   Competitive Benchmarking
        8.4.   Competitive Dashboard
            8.4.1.   Industry Leaders
            8.4.2.   Market Differentiators
            8.4.3.   Vanguards
            8.4.4.   Emerging Companies
        8.5.   Market Share Analysis/Market Ranking, by Key Players (2023)

    9.   Company Profiles (Company Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis*)
        9.1.   Lonza Group Ltd.
        9.2.   Catalent, Inc.
        9.3.   Patheon (Subsidiary of Thermo Fisher Scientific Inc.)
        9.4.   Recipharm AB
        9.5.   C.H.   Boehringer Sohn AG & CO.   KG.
        9.6.   Aurobindo Pharma, Ltd.
        9.7.   Jubilant Pharmova Limited
        9.8.   Fareva SA
        9.9.   Vetter Pharma International GmbH
        9.10.   Aenova Group
        9.11.   WuXi Biologics Co., Ltd.
        9.12.   Piramal Enterprises Limited.
        9.13.   Almac Group
        9.14.   Fabbrica Italiana Sintetici S.p.A.   (F.I.S.)
        9.15.   Samsung Biologics Co., Ltd.
        9.16.   Cambrex Corporation
        9.17.   Siegfried Holdings AG
        9.18.   FUJIFILM Diosynth Biotechnologies (Subsidiary of FUJIFILM Holdings Corporation)
        9.19.   Curia Global, Inc.
                  (Note: SWOT analysis of the top 5 companies will be provided.)

    10.   Appendix
        10.1.   Available Customization
        10.2.   Related Reports

    List of Tables
    Table 1    Global Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
    Table 2    Global Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 3    Global Pharmaceutical Manufacturing Services Market, by Country/Region, 2022-2031 (USD Million)
    Table 4    Global Active Pharmaceutical Ingredient (API) Manufacturing Services Market, by Country/Region, 2022-2031 (USD Million)
    Table 5    Global Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 6    Global Finished Dosage Forms (FDF) Manufacturing Services Market, by Country/Region, 2022-2031 (USD Million)
    Table 7    Global Parenteral/Injectable Manufacturing Services Market, by Country/Region, 2022-2031 (USD Million)
    Table 8    Global Tablet Manufacturing Services Market, by Country/Region, 2022-2031 (USD Million)
    Table 9    Global Capsule Manufacturing Services Market, by Country/Region, 2022-2031 (USD Million)
    Table 10    Global Oral Liquid Manufacturing Services Market, by Country/Region, 2022-2031 (USD Million)
    Table 11    Global Pharmaceutical Manufacturing Services Market for Other Formulations, by Country/Region, 2022-2031 (USD Million)
    Table 12    Global Drug Development Services Market, by Country/Region, 2022-2031 (USD Million)
    Table 13    Global Biologics Manufacturing Services, by Type, 2022-2031 (USD Million)
    Table 14    Global Biologics Manufacturing Services, by Country/Region, 2022-2031 (USD Million)
    Table 15    Global Active Pharmaceutical Manufacturing Services (API) Manufacturing Services Market, by Country/Region, 2022-2031 (USD Million)
    Table 16    Global Finished Dosage Form Manufacturing (FDF) Services Market, by Country/Region, 2022-2031 (USD Million)
    Table 17    Global Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
    Table 18    Global Pharmaceutical Contract Development and Manufacturing Market for Large Pharmaceutical Companies, by Country/Region, 2022-2031 (USD Million)
    Table 19    Global Pharmaceutical Contract Development and Manufacturing Market for Small & Mid-Size Pharmaceutical Companies, by Country/Region, 2022-2031 (USD Million)
    Table 20    Global Pharmaceutical Contract Development and Manufacturing Market for Generic Pharmaceutical Companies, by Country/Region, 2022-2031 (USD Million)
    Table 21    Global Pharmaceutical Contract Development and Manufacturing Market, by Country/Region, 2024–2031 (USD Million)
    Table 22    North America: Pharmaceutical Contract Development and Manufacturing Market, by Country, 2024-2031 (USD Million)
    Table 23    North America: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
    Table 24    North America: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 25    North America: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 26    North America: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 27    North America: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
    Table 28    U.S.: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
    Table 29    U.S.: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 30    U.S.: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 31    U.S.: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 32    U.S.: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
    Table 33    Canada: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
    Table 34    Canada: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 35    Canada: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 36    Canada: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 37    Canada: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
    Table 38    Europe: Pharmaceutical Contract Development and Manufacturing Market, by Country/Region, 2024-2031 (USD Million)
    Table 39    Europe: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
    Table 40    Europe: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 41    Europe: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 42    Europe: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 43    Europe: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
    Table 44    Germany: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
    Table 45    Germany: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 46    Germany: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 47    Germany: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 48    Germany: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
    Table 49    France: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2024- 2031 (USD Million)
    Table 50    France: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 51    France: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 52    France: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 53    France: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
    Table 54    U.K.: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
    Table 55    U.K.: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 56    U.K.: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 57    U.K.: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 58    U.K.: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
    Table 59    Italy: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
    Table 60    Italy: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 61    Italy: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 62    Italy: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 63    Italy: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
    Table 64    Spain: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
    Table 65    Spain: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 66    Spain: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 67    Spain: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 68    Spain: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
    Table 69    Switzerland: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
    Table 70    Switzerland: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 71    Switzerland: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 72    Switzerland: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 73    Switzerland: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
    Table 74    Netherlands: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
    Table 75    Netherlands: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 76    Netherlands: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 77    Netherlands: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 78    Netherlands: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
    Table 79    Denmark: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
    Table 80    Denmark: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 81    Denmark: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 82    Denmark: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 83    Denmark: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
    Table 84    Rest of Europe: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
    Table 85    Rest of Europe: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 86    Rest of Europe: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 87    Rest of Europe: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 88    Rest of Europe: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
    Table 89    Asia-Pacific: Pharmaceutical Contract Development and Manufacturing Market, by Country/Region, 2024-2031 (USD Million)
    Table 90    Asia- Pacific: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
    Table 91    Asia-Pacific: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 92    Asia-Pacific: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 93    Asia-Pacific: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 94    Asia-Pacific: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
    Table 95    China: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
    Table 96    China: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 97    China: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 98    China: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 99    China: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
    Table 100    India: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
    Table 101    India: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 102    India: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 103    India: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 104    India: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
    Table 105    Japan: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
    Table 106    Japan: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 107    Japan: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 108    Japan: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 109    Japan: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
    Table 110    South Korea: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
    Table 111    South Korea: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 112    South Korea: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 113    South Korea: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 114    South Korea: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
    Table 115    Australia: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
    Table 116    Australia: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 117    Australia: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 118    Australia: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 119    Australia: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
    Table 120    Singapore: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
    Table 121    Singapore: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 122    Singapore: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 123    Singapore: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 124    Singapore: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
    Table 125    Rest of Asia-Pacific: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
    Table 126    Rest of Asia-Pacific: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 127    Rest of Asia-Pacific: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 128    Rest of Asia-Pacific: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 129    Rest of Asia-Pacific: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
    Table 130    Latin America: Pharmaceutical Contract Development and Manufacturing Market, by Country/Region, 2024-2031 (USD Million)
    Table 131    Latin America: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
    Table 132    Latin America: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 133    Latin America: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 134    Latin America: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 135    Latin America: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
    Table 136    Brazil: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
    Table 137    Brazil: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 138    Brazil: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 139    Brazil: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 140    Brazil: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
    Table 141    Mexico: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
    Table 142    Mexico: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 143    Mexico: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 144    Mexico: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 145    Mexico: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
    Table 146    Rest of Latin America: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
    Table 147    Rest of Latin America: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 148    Rest of Latin America: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 149    Rest of Latin America: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 150    Rest of Latin America: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
    Table 151    Middle East & Africa: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2022-2031 (USD Million)
    Table 152    Middle East & Africa: Pharmaceutical Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 153    Middle East & Africa: Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 154    Middle East & Africa: Biologics Manufacturing Services Market, by Type, 2022-2031 (USD Million)
    Table 155    Middle East & Africa: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2031 (USD Million)
    Table 156    Recent Developments, by Company, 2021–2024

    List of Figures
    Figure 1    Research Process
    Figure 2    Key Secondary Sources
    Figure 3    Primary Research Techniques
    Figure 4    Key Executives Interviewed
    Figure 5    Breakdown of Primary Interviews (Supply Side & Demand Side)
    Figure 6    Market Size Estimation
    Figure 7    Global Pharmaceutical Contract Development and Manufacturing Market, by Type, 2024 VS. 2031 (USD Million)
    Figure 8    Global Pharmaceutical Contract Development and Manufacturing Market, by End User, 2024 VS. 2031 (USD Million)
    Figure 9    Global Pharmaceutical Contract Development and Manufacturing Market, by Geography 
    Figure 10    Impact Analysis of Market Dynamics
    Figure 11    Global Pharmaceutical Contract Development and Manufacturing Market, by Type, 2024 VS. 2031 (USD Million)
    Figure 12    Global Pharmaceutical Contract Development and Manufacturing Market, by End User, 2024 VS. 2031 (USD Million)
    Figure 13    Global Pharmaceutical Contract Development and Manufacturing Market, by Geography, 2024 VS. 2031 (USD Million)
    Figure 14    North America: Pharmaceutical Contract Development and Manufacturing Market Snapshot
    Figure 15    Europe: Pharmaceutical Contract Development and Manufacturing Market Snapshot
    Figure 16    Asia-Pacific: Pharmaceutical Contract Development and Manufacturing Market Snapshot
    Figure 17    Latin America: Pharmaceutical Contract Development and Manufacturing Market Snapshot
    Figure 18    Key Growth Strategies Adopted by Leading Players, 2021—2024
    Figure 19    Global Pharmaceutical Contract Development and Manufacturing Market: Competitive Benchmarking, by Type
    Figure 20    Global Pharmaceutical Contract Development and Manufacturing Market: Competitive Benchmarking, by Geography
    Figure 21    Global Pharmaceutical Contract Development and Manufacturing Market: Competitive Dashboard
    Figure 22    Global Pharmaceutical Contract Development and Manufacturing Market: Market Share Analysis/Market Ranking, by Key Players (2023)
    Figure 23    Thermo Fisher Scientific Inc.: Financial Snapshot (2023)
    Figure 24    C.H. Boehringer Sohn AG & CO. KG.: Financial Snapshot (2023)
    Figure 25    Catalent, Inc.: Financial Snapshot (2023)
    Figure 26    FUJIFILM Diosynth Biotechnology: Financial Snapshot (2023)
    Figure 27    Samsung Biologics: Financial Snapshot (2023)
    Figure 28    Siegfried Holding AG: Financial Snapshot (2023)
    Figure 29    Aenova Group: Financial Snapshot (2023)
    Figure 30    WuXi Biologics: Financial Snapshot (2023)
    Figure 31    Vetter Pharma International GmbH: Financial Snapshot (2023)
    Figure 32    Lonza Group Ltd.: Financial Snapshot (2023)
    Figure 33    Recipharm AB: Financial Snapshot (2023)
    Figure 34    Aurobindo Pharma ,Ltd: Financial Snapshot (2023)
    Figure 35    Jubilant Pharmova Limited: Financial Snapshot (2023) 

    Enquire
    Check Discount
    Author Name:

    Madhura Pawar, Pranjali Takale, Mahesh Khillari

    Related Tag: Pharmaceutical Contract Development and Manufacturing Market CDMO CRAMS Pharmaceutical CDMO Pharmaceutical CMO Pharmaceutical Contract Manufacturing Pharmaceutical Outsourcing Pharmaceutical Contract Manufacturing Services
    Processing & Packaging Technologies
    Healthcare
     
     
     
     

    The Pharmaceutical Contract Development and Manufacturing Market is expected to grow at a CAGR of 7.4% from 2024 to 2031 to reach $261.57 billion by 2031. Pharmaceutical contract development and manufacturing market includes pharmaceutical manufacturing services, drug development services, and biologics manufacturing services. The growth of this market is mainly attributed to factors such as complex manufacturing requirements of the pharmaceutical industry, manufacturers’ growing inclination towards the use of cutting-edge technologies, patent expiration, increasing investments in pharmaceutical R&D, the rising demand for generic medicines and biologics, and the outbreak of the COVID-19 pandemic.

    Here are the top 10 companies operating in the Pharmaceutical Contract Development and Manufacturing Market

    Lonza Group Ltd (Switzerland)

    Founded in 1952 and headquartered in Basel, Switzerland; Lonza Group is a life science-driven chemical company that supplies active ingredients, chemical intermediates, and biotechnology solutions to the pharmaceutical and agrochemical industries. The company also offers a catalog of organic intermediates for various applications, such as pharmaceuticals, agrochemicals, vitamins, food and feedstuff, dyes and pigments, adhesives, and fragrances. It also manufactures specialty biocides and oleochemicals; and develops and produces specific polymer intermediates, unsaturated polyester-resins, compounds, and composites.

    The company has a direct presence through research and development and manufacturing sites in Europe, North and Central America, Latin America, Asia, Africa, Australia, New Zealand, and other countries.

    Catalent, Inc. (U.S.)

    Founded in 2007 and headquartered in New Jersey, U.S. Catalent provides different products and services for development sciences, delivery technologies, and multi-modality manufacturing. The company works with life science customers to develop, launch, and supply pharmaceuticals, biologics, cell and gene therapy, and health products. Catalent offers development and manufacturing; formulation; and development services in pharmaceutical contract development and manufacturing market.

    The company has a direct presence through R&D and manufacturing sites in Asia-Pacific, Europe, Latin America, and North America. The company offers pharma services through its Paragon BioServices Inc. (U.S.) and Catalent Cell and Gene Therapy (U.S.) subsidiaries.

    Thermo Fisher Scientific, Inc. (U.S.)

    Founded in 2006 and headquartered in Massachusetts, U.S., Thermo Fisher Scientific offers products and services in pharmaceutical, biotechnology, agricultural, clinical, healthcare, and government markets. The company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. It offers pharmaceutical contract development and manufacturing services through the Pharma Services segment of the Laboratory Products and Biopharma Services business division.

    The company has a direct presence through its regional offices and production sites in various countries, including the U.S., Mexico, Brazil, Germany, Belgium, Austria, the U.K., Italy, the Netherlands, South Africa, the UAE, India, China, Japan, Australia, and the Republic of Korea.

    Samsung Biologics Co., Ltd. (South Korea)

    Founded in 2011 and headquartered in Incheon, South Korea, Samsung Biologics provides contract manufacturing, contract development, and clinical research services equipped with a batch production system for biopharmaceuticals. The company’s contract development business focuses on providing services for cell lines to initial clinical trials, including cell line development, process development, and formulation/analysis methodology. The clinical research business of the company offers services for the exploration of drug candidate materials, biological stability/toxicity analysis in cell line development, and homogeneity verification & cell storage.

    The company has a presence in the U.K., Germany, Japan, Australia, Nigeria, China, Canada, the U.S., Puerto Rico, Brazil, Indonesia, and Singapore, among others.

    Recipharm AB (Sweden)

    Founded in 1995 and headquartered in Sweden; Recipharm is a pharmaceutical contract development and manufacturing organization. The company’s major products and services include nasal sprays, auto-injectors, medical check valves, inhalations solutions, custom development, custom manufacturing, and generic APIs. The company operates through four business segments, namely, Advanced Delivery Systems, Manufacturing Sterile, Manufacturing Solids & Others, and Development & Licensing. The company offers its pharmaceutical products and services through its subsidiary Recipharm Pharmaceutical Development AB (Sweden) and RPH Pharmaceuticals AB (Sweden).

    The company has direct presence through its production facilities across Sweden, France, Germany, Italy, Spain, Portugal, India and the U.K. and development facilities across Sweden, France, Italy, India, Israel, and the U.S.


    FUJIFILM Diosynth Biotechnologies (Japan)

    Established in 1934 and headquartered in Tokyo, Japan, FUJIFILM Diosynth Biotechnologies is involved in developing and manufacturing active ingredients for pharmaceutical companies. The company operates through four segments: Healthcare, Business Innovation, Imaging, and Materials. The company offers cell culture services, microbial fermentation services, and viral vector & vaccine services through its Bio CDMO business segment of the Healthcare division. The company also offers additional fill-finish, process characterization, and validation services.

    FUJIFILM has facilities in the U.S., Denmark, China, Southeast Asia, and the U.K. The company has five bio CDMO facilities in Europe and the U.S. The company operates through the Healthcare business segment (sub-segment of Healthcare and Material Solutions) of its parent company FUJIFILM Holdings Corporation (Japan).

    Siegfried Holdings AG (Switzerland)

    Founded in 1873 and headquartered in Zofingen, Switzerland, Siegfried Holdings is a pharmaceutical company that offers and manufactures primary and secondary drug substances and products. It develops and manufactures active pharmaceutical ingredients for pharmaceutical clients with research and development programs, related intermediates, and controlled substances. The company also develops and produces finished dosage forms, including sterile fillings.

    Siegfried has manufacturing facilities in Switzerland, the U.S., Malta, China, Germany, France, and Spain.

    C.H. Boehringer Sohn AG & Co. KG (Germany)

    Founded in 1885 and headquartered in Ingelheim am Rhein, Germany C.H. Boehringer Sohn is a biopharmaceutical company that focuses on the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases, and oncology. The company operates through four segments, namely, Human Health, Animal Health, Biopharma Contract Manufacturing, and Science & Innovation. The Biopharma Contract Manufacturing segment offers joint development, launch, and manufacturing activities for biopharmaceutical products; contract development and manufacturing for clinical and commercial biopharmaceuticals for the external customers; and process transfer within the global biopharmaceutical supply network.

    The company has production facilities in the U.S., Spain, Brazil, Italy, Mexico, Germany, Greece, Japan, Austria, Indonesia, and China. Boehringer Ingelheim’s Biopharmaceutical Contract Manufacturing business is known under the brand name Boehringer Ingelheim BioXcellence.

    Jubilant Pharmova Limited (Limited)

    Founded in 1978 and headquartered in Uttar Pradesh, India, Jubilant Pharmova Limited, previously known as Jubilant Life Sciences Limited, is an integrated pharmaceutical and life sciences company engaged in pharmaceuticals, life science ingredients, drug discovery solutions, and branded pharmaceuticals. Jubilant Life Sciences operates in three business segments: Pharmaceuticals, Life Science Ingredients, and Drug Discovery and Development Solutions. In February 2021, Life Science Ingredients segment demerged from Jubilant Life Sciences Limited to Jubilant Ingrevia Limited, and the name of Jubilant Life Sciences Limited was changed to Jubilant Pharmova Limited. Jubilant Pharmova Ltd. offers services and products in research and manufacturing.

    The company has R&D and manufacturing sites in India, Belgium, China, the U.S., and Canada. The subsidiaries of the company operating in the CDMO market are Jubilant Biosys Limited (India), Jubilant Pharma Limited (Singapore), Jubilant HollisterStier LLC (U.S.), and Jubilant Generics Ltd. (India).

    Fareva SA (Luxembourg)

    Founded in 1985 and headquartered in Luxembourg, Fareva SA is a subcontractor in the industrial & household, cosmetics, and pharmaceutical fields. The company operates through five divisions, namely, Pharmaceuticals, API, Beauty, Makeup, Household, and Industrial. Fareva offers complete drug development and manufacturing services for APIs and intermediate active ingredients, highly potent APIs, sterile APIs, cytotoxiques drugs, and hormones and steroids. The company’s API division has a direct presence through manufacturing sites in France and Germany.

     

      This website is secure and we do not share your personal information with any third party. privacy policy
      You will also receive a PDF copy of this sample in your mailbox.

      Proudly Partnering With Enterprises Around the Globe

      Accenture Amazon BCG-Corporate BioRad Boehringer-Ingelheim Deloitte Fujifilm Intel PEPSICO Samsung Olympus McKinsey LG-Chem Rosetta-Stone tata-consultancy-services SK Kao IQVIA Vemag Canada Genscript Grupo-Vilaseca HEC Highland-Metals-Inc
      Related Tag: Pharmaceutical Contract Development and Manufacturing Market CDMO CRAMS Pharmaceutical CDMO Pharmaceutical CMO Pharmaceutical Contract Manufacturing Pharmaceutical Outsourcing Pharmaceutical Contract Manufacturing Services
      Request Sample
      Customize My Report
      Quick Contact
      Chat on Whatsapp
      Linkdin
      Whatsapp
      Feed
      Related Reports
      South East Asia Pharmaceutical Contract Development and Manufacturing Market - Opportunity Analysis and Industry Forecast (2025-2032)

         Published Date: Jan-2025

      Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market - Opportunity Analysis and Industry Forecast (2025-2032)

         Published Date: Jan-2025

      North America Pharmaceutical Contract Development and Manufacturing Market - Opportunity Analysis and Industry Forecasts (2025-2032)

         Published Date: Jan-2025

      Europe Pharmaceutical Contract Development and Manufacturing Market - Opportunity Analysis and Industry Forecast (2025-2032)

         Published Date: Jan-2025

      Medical Device Contract Manufacturing Market - Global Opportunity Analysis and Industry Forecast (2025-2032)

         Published Date: Sep-2024

      Table Of Content
      Download Free Sample Report
      Meticulous Research
      US
      +1 646-781-8004
      Meticulous Research
      Europe
      +44-203-868-8738
      Meticulous Research
      APAC
      +91-744-778-0008